Compounded GLP-1 drugs creating concern among doctors and FDA
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Compounded GLP-1 drugs creating concern among doctors and FDA" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include The Star-Herald, MedPage Today, WAPT and qz.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 106d ago.
Quick answers
Why is "Compounded GLP-1 drugs creating concern among doctors and FDA" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- News You Can Use: What to Know Before You Buy GLP-1s Online The Star-Herald · 108d ago
- Troubling Findings in Study of GLP-1 Compounders MedPage Today · 108d ago
- Ole Miss researchers warn cheaper knockoff weight-loss drugs may pose health risks WAPT · 108d ago
- FDA warns on compounded GLP-1 weight loss drugs qz.com · 108d ago
- Compounded GLP-1 drugs creating concern among doctors and FDA NewsNation · 108d ago
Topics
Related trends
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
Pfizer has secured up to $1.5 billion from Blackstone to fund the development of its obesity and weight-loss drugs.
Christina Applegate fears that ‘poisoning’ may be behind her misdiagnosis of MS
Christina Applegate reveals she is investigating whether breast implant illness caused her multiple sclerosis misdiagnosis, calling it potential 'poisoning.'
Moderna chasing ‘holy grail’ of cancer prevention
Moderna is targeting a universal cancer shot and chasing the holy grail of prevention as stock rises.
Some people are having hallucinations and other psychotic symptoms after stopping GLP-1 drugs
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.